QS Investors’s Arcus Biosciences RCUS Stock Holding History

QS Investors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-28,300	Closed	-$701K	–	1466
2020 Q2	$701K	Buy	+28,300	New	+$764K	0.01%	827

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

QS Investors's RCUS Position: Q3 2020 in Review

QS Investors sold out of Arcus Biosciences (RCUS) in Q3 2020, closing a stake of 28,300 shares — an estimated $701K sold.

QS Investors first reported a position in RCUS in Q2 2020 and held it in 1 quarter. The position peaked at $701K in Q2 2020. 128 funds tracked by Wall St. Rank hold RCUS as of Q3 2020.

QS Investors reported no remaining Arcus Biosciences position as of Q3 2020 after selling out during the quarter.
QS Investors sold 28,300 Arcus Biosciences shares in Q3 2020, an estimated $701K.
QS Investors first reported a position in Arcus Biosciences in Q2 2020 and held it in 1 quarter.
QS Investors's Arcus Biosciences position peaked at $701K in Q2 2020.
128 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.